-
TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Armin Frille, Myriam Boeschen, Hubert Wirtz, Mathias Stiller, Hendrik Bläker, Maximilian von Laffert
BackgroundRecently, we could show that the co-mutations of KRAS + KEAP1, STK11 + KEAP1 and KRAS + STK11 + KEAP1 lead to a significantly shorter median overall survival (mOS) across treatments by analyzing multiple datasets. TP53, a tumor suppressor gene, plays a crucial role in regulating cell cycle progression. Its mutations occur in approximately 40-50% of non-small lung cancer (NSCLC). Co-occurrence
-
Case report: Report of a rare encounter: metastasis of renal cell carcinoma to the thyroid Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Siyi Xu, Jiawei Xu, Chengdong Yu, Ying Zeng, Lei Tang, Mu Tang, Tenghua Yu, Zhengkui Sun, Xiaofang Zhang
Renal cell carcinoma (RCC) is the most common renal tumor, with lung, bone, and liver being the primary sites of metastasis. Thyroid metastasis, on the other hand, is relatively uncommon. Metastatic tumors in the thyroid gland typically manifest as multiple or isolated nodules, which can be easily overlooked due to the lack of specific clinical and imaging features. However, the identification of thyroid
-
Predicting histologic grades for pancreatic neuroendocrine tumors by radiologic image-based artificial intelligence: a systematic review and meta-analysis Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Qian Yan, Yubin Chen, Chunsheng Liu, Hexian Shi, Mingqian Han, Zelong Wu, Shanzhou Huang, Chuanzhao Zhang, Baohua Hou
BackgroundAccurate detection of the histological grade of pancreatic neuroendocrine tumors (PNETs) is important for patients’ prognoses and treatment. Here, we investigated the performance of radiological image-based artificial intelligence (AI) models in predicting histological grades using meta-analysis.MethodA systematic literature search was performed for studies published before September 2023
-
Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Bruna Fernandes, Jyoti Roy, Falguni Basuli, Blake M. Warner, Liza Lindenberg, Esther Mena, Steven S. Adler, Gary L. Griffiths, Peter L. Choyke, Frank I. Lin
IntroductionProstate-specific membrane antigen (PSMA) is present in high amounts in salivary glands, but it is unclear whether labeled binders of PSMA are excreted in the saliva.MethodsTen patients with prostate cancer underwent whole-body [18F]DCFPyL PET/CT (NCT03181867), and saliva samples were collected between 0-120 minutes post-injection. [18F]DCFPyL salivary excretion was measured over 120 minutes
-
Exploration of identifying individual tumor tissue based on probabilistic model Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Yuhan Hu, Qiang Zhu, Xuan Dai, Mengni Zhang, Nanxiao Chen, Haoyu Wang, Yuting Wang, Yueyan Cao, Yufang Wang, Ji Zhang
Variations in the tumor genome can result in allelic changes compared to the reference profile of its homogenous body source on genetic markers. This brings a challenge to source identification of tumor samples, such as clinically collected pathological paraffin-embedded tissue and sections. In this study, a probabilistic model was developed for calculating likelihood ratio (LR) to tackle this issue
-
Favorable outcome of immunotherapy in a rare subtype of hepatocellular carcinoma: a case report and literature review Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Anita Archwamety, Nique Kunapinun, Sirinart Sirinvaravong, Piyaporn Apisarnthanarak, Charuwan Akewanlop, Krittiya Korphaisarn
Scirrhous hepatocellular carcinoma (S-HCC) represents an uncommon subtype of HCC. During radiological evaluation this unique subtype is frequently mistaken as cholangiocarcinoma, fibrolamellar HCC, or metastatic adenocarcinoma. Here, we present the case of a 50-year-old woman with a large hepatic mass. A triple-phase computed tomography of the liver revealed an arterial enhancing lesion without portovenous
-
Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Huimin Zhang, Xiaofeng Cong, Jiaxin Yin, Chen Chen, Ziling Liu
The v-raf murine sarcoma viral oncogenic homolog B1 (BRAF) V600E is a rare mutation that functions as an oncogenic driver in patients with non-small cell lung cancer (NSCLC) leading to the overactivation of the RAS-RAF-MEK-ERK (MAPK) pathway and the subsequent uncontrolled cell proliferation. Understanding the mechanism behind BRAF mutation, its inhibition, and relationship to the upstream and downstream
-
Case report: Nutritionally supported perioperative chemo-immunotherapy for advanced gastric cancer with incomplete pyloric obstruction Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Mi Jian, Zhensong Yang, Xue Hu, Xixun Wang, Zhenbin Zhang, Yifei Zhang, Xinna Song
This case describes the benefits of perioperative chemo-immunotherapy for advanced gastric cancer and incomplete pyloric obstruction, supplemented with nutritional support. Early parenteral nutrition to stabilize nutritional status and mitigate nutrition impact symptoms, and in addition, throughout the chemo-immunotherapy perioperative period also maintained oral nutrition support and a tailored dietary
-
Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Dong Won Baek, Ga-Young Song, Ho Sup Lee, Young Rok Do, Ji Hyun Lee, Ho-Young Yhim, Joon Ho Moon, Deok-Hwan Yang
BackgroundElderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) undergoing reduced intensity R-CHOP therapy are at a heightened risk of acquiring infections, notably coronavirus disease 2019 (COVID-19) infection. This study aimed to evaluate the efficacy of intravenous immunoglobulin (IVIG) as prophylaxis against COVID-19 in this vulnerable population.MethodsA total of 125 elderly patients
-
Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
The progression pattern of tumors has an impact on the survival of patients with advanced hepatocellular carcinoma (HCC) and has been applied in the design of clinical trials for multiple second-line drugs. Previous research results have been contradictory, and the clinical impact of different progression patterns and their role in survival are still in question.PurposeThe study aims to analyze the
-
Microwave ablation for painful chest wall metastases from gastrointestinal stromal tumor: a case report Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Shishi Wang, Lu Wang, Tingting Li, Yuan Li, Min Zhuang, Man Lu
BackgroundGastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive tract, with the potential to metastasize. Metastases to bone and soft tissue are more frequent in advanced cases, where targeted therapy is the standard treatment. However, around 10–15% of patients develop disease progression despite treatment. Studies have shown the efficacy of ablation in managing
-
The functional role of Nudt2 in human triple negative breast cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Rasha Abu-Rahmah, Hovav Nechushtan, Sanaa Hidmi, Amichay Meirovitz, Ehud Razin, Tamar Peretz
The main known function of Nudix hydrolase 2 (Nudt2) is to hydrolyze the secondary messenger diadenosine 5’, 5’’’-p1, p4-tetraphosphate (Ap4A). In this study we examined the role of Nudt2 in breast carcinoma through its expression in human invasive ductal carcinoma tissues, and its functions in human triple negative breast cancer (TNBC) cell lines. A significantly higher expression of Nudt2 was observed
-
Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Xiao Ling, Gregory S. Alexander, Jason Molitoris, Jinhyuk Choi, Lisa Schumaker, Phuoc Tran, Ranee Mehra, Daria Gaykalova, Lei Ren
IntroductionThis study aimed to identify CT-based imaging biomarkers for locoregional recurrence (LR) in Oral Cavity Squamous Cell Carcinoma (OSCC) patients.MethodsComputed tomography scans were collected from 78 patients with OSCC who underwent surgical treatment at a single medical center. We extracted 1,092 radiomic features from gross tumor volume in each patient’s pre-treatment CT. Clinical characteristics
-
Cancer related cognitive impairment: a downside of cancer treatment Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Kimberly Demos-Davies, Jessica Lawrence, Davis Seelig
Cancer treatment is associated with long lasting cognitive impairment in cancer survivors. This cognitive impairment is often termed cancer related cognitive impairment (CRCI). Cancer survivors treated for tumors outside the central nervous system are increasingly diagnosed with CRCI. The development of strategies to mitigate the negative effects of cancer treatment on the brain are crucial. Although
-
Cervical cancer prevention by vaccination: review Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Julio Cesar González-Rodríguez, Aurelio Cruz-Valdez, Vicente Madrid-Marina
Routine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.ObjectiveTo review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination
-
The safety and use of perioperative dexamethasone in the perioperative management of primary sporadic supratentorial meningiomas Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Felix Arlt, Alim Emre Basaran, Markus Vogel, Martin Vychopen, Clemens Seidel, Alonso Barrantes-Freer, Erdem Güresir, Johannes Wach
ObjectiveDespite the lack of prospective evidence for the perioperative use of dexamethasone in meningioma surgery, its use is well established in the daily routine of several centers. The present study evaluates the effect of dexamethasone on postoperative complications, peritumoral T2/FLAIR hyperintensity, and progression-free survival in patients with supratentorial meningiomas undergoing resection
-
ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Rui Chen, Yan Jian, Yuzhen Liu, Junping Xie
BackgroundCases of ALK-rearranged EGFR wild-type lung adenocarcinoma (LUAD) transforming into small cell lung cancer (SCLC) are rarely reported, and diagnosis is often delayed. The emergence of this transformation phenomenon is often regarded as a consequence of acquired resistance mechanisms.Case presentationA 47-year-old male diagnosed with poorly differentiated adenocarcinoma of the right middle
-
Gastric-type endocervical adenocarcinoma: a case report and literature review Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Xiao Wen, Li Yu, Xiangyu Liu, Xinjia He, Yuanyuan Zhao, Guoliang Li
Gastric-type endocervical adenocarcinoma (G-EAC) represents a rare variant of cervical mucinous adenocarcinoma that is typically unrelated to human papillomavirus (HPV) infection. G-EAC exhibits highly atypical clinical presentations and characteristics, and aggressive biological behavior often leads to challenges in timely diagnosis. Here, we present a case study involving a 74-year-old Chinese woman
-
Chronic disease comorbidity and associated factors among cancer patients in eastern Ethiopia Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Abdi Birhanu, Michael Shawel Lemma, Biruk Habtamu, Nahom Wondwossen Worku, Monas Kitessa, Shambel Nigusie, Galana Mamo Ayana, Yehenaw Tenaw, Selamawit Sete, Bedasa Taye Merga, Ibsa Mussa
BackgroundThe occurrence of long-lasting comorbidities makes cancer management and treatment challenging because of their overlapping poor prognosis. However, there are no data that show the burden of these chronic cases in patients with cancer in Ethiopia. Therefore, this study aimed to assess the burden of and the factors associated with chronic disease comorbidity among cancer patients in the eastern
-
Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Karl F. B. Payne, Peter Brotherwood, Harini Suriyanarayanan, Jill M. Brooks, Nikolaos Batis, Andrew D. Beggs, Deena M. A. Gendoo, Hisham Mehanna, Paul Nankivell
BackgroundAs circulating tumour DNA (ctDNA) liquid biopsy analysis is increasingly incorporated into modern oncological practice, establishing the impact of genomic intra-tumoural heterogeneity (ITH) upon data output is paramount. Despite advances in other cancer types the evidence base in head and neck squamous cell carcinoma (HNSCC) remains poor. We sought to investigate the utility of ctDNA to detect
-
LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients Front. Oncol. (IF 4.7) Pub Date : 2024-04-23 Hagar Eltorky, Manar AbdelMageed, Hager Ismail, Faten Zahran, Adel Guirgis, Lina Olsson, Gudrun Lindmark, Marie-Louise Hammarström, Sten Hammarström, Basel Sitohy
IntroductionThe aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16.MethodsLGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses.ResultsPatients
-
RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Sarah J. Taylor, Robert L. Hollis, Charlie Gourley, C. Simon Herrington, Simon P. Langdon, Mark J. Arends
BackgroundDNA damage repair is frequently dysregulated in high grade serous ovarian cancer (HGSOC), which can lead to changes in chemosensitivity and other phenotypic differences in tumours. RFWD3, a key component of multiple DNA repair and maintenance pathways, was investigated to characterise its impact in HGSOC.MethodsRFWD3 expression and association with clinical features was assessed using in
-
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Yifan Pang, Nilanjan Ghosh
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies. Despite the success, treatment failure due to CD19 antigen loss, mutation, or down-regulation remains the main obstacle to cure. On-target, off-tumor effect of CD19-CAR T leads to side effects such as prolonged B-cell aplasia, limiting
-
The FLASH effect—an evaluation of preclinical studies of ultra-high dose rate radiotherapy Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Josie May McGarrigle, Kenneth Richard Long, Yolanda Prezado
FLASH radiotherapy (FLASH-RT) is a novel radiotherapy approach based on the use of ultra-high dose radiation to treat malignant cells. Although tumours can be reduced or eradicated using radiotherapy, toxicities induced by radiation can compromise healthy tissues. The FLASH effect is the observation that treatment delivered at an ultra-high dose rate is able to reduce adverse toxicities present at
-
Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Jianbiao Zhou, Wee-Joo Chng
Acute myeloid leukemia (AML) is a complex and heterogeneous group of aggressive hematopoietic stem cell disease. The presence of diverse and functionally distinct populations of leukemia cells within the same patient’s bone marrow or blood poses a significant challenge in diagnosing and treating AML. A substantial proportion of AML patients demonstrate resistance to induction chemotherapy and a grim
-
Myelopreservation with Trilaciclib in recurrent advanced ovarian cancer: a case report Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Huaming Tan, Xiuchen Han, Chao Li, Wenli Liu, Kanghong Li, Xiugui Sheng, Shuying Qi
Ovarian cancer is a prevalent malignant tumor of the female reproductive system, often remaining concealed until it reaches an advanced stage. The standard treatment protocol includes cytoreductive surgery for ovarian cancer plus postoperative consolidation chemotherapy and maintenance therapy, although it carries a high recurrence rate. During the treatment period, chemotherapy can lead to bone marrow
-
Circ_0003945: an emerging biomarker and therapeutic target for human diseases Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Xiaofei Zhang, Li Ma, Li Wan, Haoran Wang, Zhaoxia Wang
Due to the rapid development of RNA sequencing techniques, a circular non-coding RNA (ncRNA) known as circular RNAs (circRNAs) has gradually come into focus. As a distinguished member of the circRNA family, circ_0003945 has garnered attention for its aberrant expression and biochemical functions in human diseases. Subsequent studies have revealed that circ_0003945 could regulate tumor cells proliferation
-
Ectopic thyroid in the hepatoduodenal ligament: a case report and literature review Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Lei Zhang, Xijun Cui, Baolei Wang, Xiulan Du, Guoqi Hou, Xiaoqian Yu
Ectopic thyroid arises from abnormal development of thyroid primordial tissues as it migrates to the lower interstitium during the embryonic period, which can occur at various locations during the descent process. However, ectopic thyroid in the subdiaphragmatic area is extremely rare. In this case, we report a case of ectopic thyroid located in the hepatoduodenal ligament. The 60-year-old female patient
-
Changing trends in the disease burden of uterine cancer globally from 1990 to 2019 and its predicted level in 25 years Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Shuang Song, Dandan Zhang, Yizi Wang, Zixuan Song
BackgroundWe aim to evaluate the global, regional, and national burden of Uterine Cancer (UC) from 1990 to 2019.MethodsWe gathered UC data across 204 countries and regions for the period 1990-2019, utilizing the Global Burden of Disease Database (GBD) 2019 public dataset. Joinpoint regression analysis was employed to pinpoint the year of the most significant changes in global trends. To project the
-
Health-related quality of life in patients with peripheral nerve tumors: results from the German multicentric Peripheral Nerve Tumor Registry Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Nadja Grübel, Gregor Antoniadis, Uerschels AK, Benjamin Mayer, Ralph König, Christian Rainer Wirtz, Andrej Pala, Nora F. Dengler, Maria Teresa Pedro
ObjectivePeripheral nerve tumors (PNTs) are rare diseases. So far, no multicenter data on diagnostics, the efficacy of treatment, long-term outcomes, and health-related quality of life (HRQoL) exist. The establishment of the Peripheral Nerve Tumor Registry (PNTR) in 2015 allows for the systematic analysis of patients with tumors associated with peripheral nerves. The present study aims to investigate
-
Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Wenjuan Zhong, Longqiu Wu, Lixing Huang, Jianfeng Wang, Huaqiu Shi, Shugui Wu
Leptomeningeal metastasis (LM) is a complication of non-small cell lung cancer (NSCLC) characterized by poor prognosis and short survival. A variety of therapeutic approaches have been sought to improve the efficacy of LM. Here we present a clinical case and conduct a literature review to investigate the effectiveness and safety of double-dose osimertinib combined with a pemetrexed intrathecal injection
-
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-22 Blaine Brower, Asia McCoy, Hiba Ahmad, Cheryl Eitman, I. Alex Bowman, Jennifer Rembisz, Matthew I. Milowsky
Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, and pembrolizumab, an immune checkpoint inhibitor, are two therapies that have individually provided a survival benefit in patients with la/mUC. The combination regimen of enfortumab vedotin plus
-
The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Yujie Huang, Daitian Zheng, Zhongming Zhou, Haiting Wang, Yanpo Li, Huihui Zheng, Jianhui Tan, Jingyao Wu, Qiuping Yang, Huiting Tian, Liuming Lin, Zhiyang Li, Tianyu Li
IntroductionCancer represents a significant global public health concern. In recent years, the incidence of cancer has been on the rise worldwide due to various factors, including diet, environment, and an aging population. Simultaneously, advancements in tumor molecular biology and genomics have led to a shift from systemic chemotherapy focused on disease sites and morphopathology towards precise
-
The use of technology in cancer prehabilitation: a systematic review Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 San San Tay, Fuquan Zhang, Edmund Jin Rui Neo
AimThis review aimed to evaluate the effectiveness and feasibility of cancer prehabilitation programs delivered through technological enablers compared to conventional face-to-face interventions.MethodsA systematic review was conducted, searching PubMed, Embase, and CINAHL for studies published from inception to February 6, 2024. Studies were included if they involved adult cancer patients in primary
-
The prognostic value of co-expression of stemness markers CD44 and CD133 in endometrial cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Peng Jiang, Chenfan Tian, Yunfeng Zheng, Chunxia Gong, Jinyu Wang, Ying Liu
ObjectiveThe purpose of this study was to investigate the correlation between stemness markers (CD44 and CD133) and clinical pathological features, and to further explore the prognostic value of co-expression of CD44 & CD133 in endometrial cancer (EC).MethodsClinical data of stage I-III EC patients who underwent initial surgical treatment at two large tertiary medical centers from 2015 to 2020 were
-
Biomarkers of chemotherapy-induced cardiotoxicity: toward precision prevention using extracellular vesicles Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Brian B. Silver, Anna Kreutz, Madeleine Weick, Kevin Gerrish, Erik J. Tokar
Detrimental side effects of drugs like doxorubicin, which can cause cardiotoxicity, pose barriers for preventing cancer progression, or treating cancer early through molecular interception. Extracellular vesicles (EVs) are valued for their potential as biomarkers of human health, chemical and molecular carcinogenesis, and therapeutics to treat disease at the cellular level. EVs are released both during
-
Nutritional status, body composition and diet quality in children with cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Magdalena Schab, Szymon Skoczen
During cancer treatment, nutritional status disorders such as malnutrition or obesity affect the tolerance of cancer treatment, quality of life, but also the pharmacokinetics of drugs. It is hypothesized that changes in fat and lean body mass can modify chemotherapy volume distribution, metabolism and clearance. In children with cancer, lean body mass decreases or remains low during treatment and fat
-
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibodies (ADAs). Tofacitinib is an oral Janus Kinase (JAK) inhibitor that prevented ADA formation against iTox in preclinical studies.MethodsA phase 1 trial
-
Case report: Immunotherapy inducing unexpected overall survival in choroidal melanoma: about a case Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Youssef Elhaitmy, Soukaina El Anssari, Pierre Fournel, Nawfel Mellas, Wafa Bouleftour, Michele Lamuraglia
Choroidal melanoma (CM) is the most common malignant ocular tumor in adults. The current treatment of metastatic CM is limited by the intrinsic resistance of CM to conventional systemic therapies. Immunotherapy alone or in association with cytotoxic treatment became a realist option treatment. Advancements in molecular biology have resulted in the identification of a number of promising prognostic
-
Case report: A case of recurrent cervical cancer with bronchial and esophageal metastases presenting with hemoptysis and dysphagia Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Xiao Yu, Shixiang Dong, Wenjie Wang, Xin Sun, Yankui Wang, Fengsheng Yu
BackgroundThe treatment outcomes and prognosis for recurrent cervical cancer are generally poor, with a 5-year survival rate of only 10%–20%.Case presentationIn this case, the patient is a young woman who experienced a recurrence 5 years after the initial treatment of cervical cancer. Her primary symptoms were hemoptysis and dysphagia, indicative of hilar and mediastinal lymph node metastases, with
-
The role of P3H family in cancer: implications for prognosis, tumor microenvironment and drug sensitivity Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Ziyun Wang, Hua Wang
IntroductionProlyl 3-hydroxylases (P3H) are crucial enzymes in collagen biosynthesis and are known to be involved in a variety of physiological processes. However, their specific roles in cancer progression, modulation of the tumor microenvironment (TME), and impact on patient prognosis remain areas that require further investigation.MethodsThe investigation involved a comprehensive analysis of expression
-
The coexistence of myosteatosis and the creatinine/cystatin C ratio are determinants of outcomes in cholangiocarcinoma patients undergoing curative surgery Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Yan Liu, Jingli Zhang, Guanghui Song, Xueli Ding, Hui Sun, Jianrui Zhou, Xue Jing
BackgroundMyosteatosis is a well-established predictor of poor prognosis in many types of cancer, and a decreased Creatinine/Cystatin C ratio (CCR) is a known indicator of unfavorable outcomes in patients with metabolic disorders and cancer. Despite this knowledge, the significance of concurrent CCR and myosteatosis in predicting the prognosis of patients with cholangiocarcinoma (CCA) who undergo radical
-
Dynamic three-dimensional liver volume assessment of liver regeneration in hilar cholangiocarcinoma patients undergoing hemi-hepatectomy Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Haoyu Zhao, Baifeng Li, Xiaohang Li, Xiangning Lv, Tingwei Guo, Zongbo Dai, Chengshuo Zhang, Jialin Zhang
BackgroundFor patients with hilar cholangiocarcinoma (HC) undergoing hemi-hepatectomy, there are controversies regarding the requirement of, indications for, and timing of preoperative biliary drainage (PBD). Dynamic three-dimensional volume reconstruction could effectively evaluate the regeneration of liver after surgery, which may provide assistance for exploring indications for PBD and optimal preoperative
-
Host-gut microbiota derived secondary metabolite mediated regulation of Wnt/β-catenin pathway: a potential therapeutic axis in IBD and CRC Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Sushma S. Kumar, Ashna Fathima, Preeti Srihari, Trinath Jamma
The intestinal tract encompasses one of the largest mucosal surfaces with a well-structured layer of intestinal epithelial cells supported by a network of underlying lamina propria immune cells maintaining barrier integrity. The commensal microflora in this environment is a major contributor to such functional outcomes due to its prominent role in the production of secondary metabolites. Of the several
-
Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Maria T. Bourlon, Shaddai Urbina-Ramirez, Haydee C. Verduzco-Aguirre, Mauricio Mora-Pineda, Hugo E. Velazquez, Eucario Leon-Rodriguez, Yemil Atisha-Fregoso, María G. De Anda-Gonzalez
IntroductionPatients with adverse pathological features (APF) at radical prostatectomy (RP) for prostate cancer (PC) are candidates for adjuvant treatment. Clinicians lack reliable markers to predict these APF preoperatively. Protein tyrosine phosphatase 1B (PTP-1B) is involved in migration and invasion of PC, and its expression could predict presence of APF. Our aim was to compare PTP-1B expression
-
Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Siyuan Huang, Linlin Li, Ningning Yan, Huixian Zhang, Qianqian Guo, Sanxing Guo, Di Geng, Xincheng Liu, Xingya Li
BackgroundHighly selective type Ib mesenchymal–epithelial transition gene (MET) tyrosine kinase inhibitors (TKIs) are the standard-of-care (SOC) therapy for previously untreated non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. However, there are rare reports describing effective regimens for patients who fail SOC without identifying resistant mutations or tissue
-
Case report: Systemic presentation of ALK-positive Histiocytosis Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Yongbao Wei, Ruochen Zhang, Deng Lin, Xiaoyan Chen, Lizhi Li, Haijian Huang
ALK-positive Histiocytosis (ALK-HSs) is a recently identified rare clinical entity characterized by tissue histiocytic alterations associated with ALK gene rearrangement. Clinical presentations can be solitary, multifocal, or systemic (involving multiple sites and organs). Due to limited reported cases, there is inadequate understanding of this disease. This report presents a case of ALK-HSs in a 71-year-old
-
An invasion front gene expression signature for higher-risk patient selection in stage IIA MSS colon cancer Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Eva Budinská, Martina Čarnogurská, Tina Catela Ivković, Táňa Macháčková, Marie Boudná, Lucie Pifková, Ondřej Slabý, Beatrix Bencsiková, Vlad Popovici
Stage II colon cancer (CC) encompasses a heterogeneous group of patients with diverse survival experiences: 87% to 58% 5-year relative survival rates for stages IIA and IIC, respectively. While stage IIA patients are usually spared the adjuvant chemotherapy, some of them relapse and may benefit from it; thus, their timely identification is crucial. Current gene expression signatures did not specifically
-
Quantitative ultrasound radiomics guided adaptive neoadjuvant chemotherapy in breast cancer: early results from a randomized feasibility study Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Archya Dasgupta, Daniel DiCenzo, Lakshmanan Sannachi, Sonal Gandhi, Rossana C. Pezo, Andrea Eisen, Ellen Warner, Frances C. Wright, Nicole Look-Hong, Ali Sadeghi-Naini, Belinda Curpen, Michael C. Kolios, Maureen Trudeau, Gregory J. Czarnota
BackgroundIn patients with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy (NAC), quantitative ultrasound (QUS) radiomics can predict final responses early within 4 of 16-18 weeks of treatment. The current study was planned to study the feasibility of a QUS-radiomics model-guided adaptive chemotherapy.MethodsThe phase 2 open-label randomized controlled trial included patients
-
Malignant phyllodes tumor of the breast with predominant osteosarcoma and chondrosarcomatous differentiation: a rare case report and review of literature Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Wenfang Li, Qin Ou, Yingdong Li, Linlin Yuan Yuan
BackgroundPhyllodes tumors (PTs), which account for less than 1% of mammary gland tumors, composed of both epithelial and stromal components. If a malignant heterologous component is encountered, PT is considered malignant. Malignant phyllodes tumors (MPTs) only account for 8% to 20% of PTs. We report a case of MPT with osteosarcoma and chondrosarcoma differentiation and review the literature to discuss
-
Molecular characterization of the evolution of premalignant lesions in the upper aerodigestive tract Front. Oncol. (IF 4.7) Pub Date : 2024-04-19 Axel Lechner, Jörg Kumbrink, Christoph Walz, Andreas Jung, Philipp Baumeister, Susanne Flach
IntroductionEarly relapse and development of metastatic disease are some of the primary reasons for the poor prognosis of patients with head and neck squamous cell carcinoma (HNSCC). HNSCC is a heterogeneous disease which may develop in large premalignant fields of genetically altered cells. Yet knowing which individuals will progress and develop clinically significant cancers during their lifetimes
-
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Charles J. Milrod, Ari Pelcovits, Thomas A. Ollila
Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory (R/R) regimens. In first-line therapy, the synergy between ICIs and chemotherapy may surpass the previous standards of ABVD and BV-AVD established by landmark trials including RATHL and ECHELON-1. In R/R disease, the combination
-
Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Yutong Lu, Jingqi Jiang, Gaoyang Yang, Hui Ding, Qihui Zheng, Luhua Ji, Yuhan Wang, Zhilong Dong, Zhenxing Zhai, Junqiang Tian, Yunxing Zhang, Juan Wang, Li Yang, Zhiping Wang
BackgroundThe current treatment strategy for metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is the combination of Androgen Receptor Signaling Inhibitors (ARSIs) medicines with androgen deprivation therapy (ADT). However, there is a lack of real-world data comparing the efficacy of different ARSI pharmaceuticals. Therefore, the objective of this study was to compare the effectiveness and safety
-
Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance. Resistance mechanisms to ALK TKIs can be broadly classified into ALK-dependent and ALK-independent pathways. Here, we present a case with lung adenocarcinoma (LUAD) harboring an ALK rearrangement
-
GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Fionnuala Crowley, Stav Brown, Emily J. Gallagher, Joseph H. Dayan
IntroductionLymphedema is a major public health issue for many women undergoing breast cancer treatment. Although weight loss has been reported to be beneficial in the treatment of lymphedema, no studies to date have examined the use of GLP-1RAs for the treatment of secondary lymphedema. This case report describes a patient who experienced significant resolution of her breast cancer-related lymphedema
-
Delaying age at first sexual intercourse provides protection against oral cavity cancer: a mendelian randomization study Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Ting Sun, Xin He, Xing Chen, Yang Huaqing, Haimei Zhang, Min Zhao, Li Du, Bin Zhao, Junping Hou, Xudong Li, Yu Liu
AimTo investigate whether age at first sexual intercourse could lead to any changes in the risk of oral cavity cancer.MethodsA two-sample mendelian randomization was conducted using genetic variants associated with age at first sexual intercourse in UK biobank as instrumental variables. Summary data of Northern American from a previous genome-wide association study aimed at oral cavity cancer was served
-
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
BackgroundFront-line therapy with an EGFR tyrosine kinase inhibitor (TKI) is the standard of care for treating patients with advanced nonsquamous NSCLC with the common sensitizing EGFR exon 19 deletion and exon 21 L858R point mutations. However, EGFR TKI resistance inevitably develops. The optimal subsequent therapy remains to be identified, although platinum-containing chemotherapy regimens are often
-
App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship – a multicentric randomized controlled trial Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Josefine Wolff, Svenja Seidel, Pia Wuelfing, Michael Patrick Lux, Christine zu Eulenburg, Martin Smollich, Freerk Baumann, Stephan Seitz, Sherko Kuemmel, Marc Thill, Joke Tio, Michael Braun, Hannah Hollaender, Angenla Seitz, Felicitas Horn, Nadia Harbeck, Rachel Wuerstlein
IntroductionThe negative impact of unmanaged psychological distress on quality of life and outcome in breast cancer survivors has been demonstrated. Fortunately, studies indicate that distress can effectively be addressed and even prevented using evidence-based interventions. In Germany prescription-based mobile health apps, known as DiGAs (digital health applications), that are fully reimbursed by
-
Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2 Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Chidiebere U. Awah, Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Martin Nzegwu, Hiroshi Matsui, Olorunseun Ogunwobi
Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate, and brain cancers combined. This is primarily due to their aggressive metastatic nature, leading to more fatal rates of cancer patients. Despite this condition, there are no clinically approved drugs that can target metastasis. The NSCLC with EGFR T790M-overexpressing HER2 shows the resistance to osimertinib
-
Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression Front. Oncol. (IF 4.7) Pub Date : 2024-04-18 Hong Tian, Jia-Li Yu, Xiaoli Chu, Qi Guan, Juan Liu, Ying Liu
C1GALT1 plays a pivotal role in colorectal cancer (CRC) development and progression through its involvement in various molecular mechanisms. This enzyme is central to the O-glycosylation process, producing tumor-associated carbohydrate antigens (TACA) like Tn and sTn, which are linked to cancer metastasis and poor prognosis. The interaction between C1GALT1 and core 3 synthase is crucial for the synthesis